Novo Nordisk A/S (NYSE:NVO) Shares Down 0.2%

Novo Nordisk A/S (NYSE:NVO)’s share price dropped 0.2% during trading on Tuesday . The stock traded as low as $128.44 and last traded at $128.85. Approximately 1,359,717 shares were traded during trading, a decline of 74% from the average daily volume of 5,232,224 shares. The stock had previously closed at $129.05.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. TD Cowen raised their price target on shares of Novo Nordisk A/S from $105.00 to $115.00 and gave the stock an “outperform” rating in a research report on Monday, December 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, March 20th. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective for the company. Finally, UBS Group began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating for the company. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus price target of $126.25.

Novo Nordisk A/S Stock Performance

The company has a current ratio of 0.82, a quick ratio of 0.64 and a debt-to-equity ratio of 0.19. The company’s 50-day moving average is $121.34 and its two-hundred day moving average is $104.22. The stock has a market capitalization of $574.63 billion, a P/E ratio of 47.34, a P/E/G ratio of 2.13 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. The firm had revenue of $9.51 billion for the quarter, compared to analysts’ expectations of $9.14 billion. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.35 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a Semi-Annual dividend, which will be paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th will be paid a dividend of $0.664 per share. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date of this dividend is Friday, March 22nd. This represents a yield of 0.9%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 49.17%.

Institutional Trading of Novo Nordisk A/S

A number of institutional investors have recently made changes to their positions in NVO. Chilton Capital Management LLC lifted its stake in Novo Nordisk A/S by 0.6% during the second quarter. Chilton Capital Management LLC now owns 10,063 shares of the company’s stock valued at $1,628,000 after purchasing an additional 63 shares during the last quarter. IHT Wealth Management LLC increased its stake in shares of Novo Nordisk A/S by 3.5% in the fourth quarter. IHT Wealth Management LLC now owns 2,369 shares of the company’s stock worth $321,000 after acquiring an additional 80 shares during the last quarter. U.S. Capital Wealth Advisors LLC boosted its position in Novo Nordisk A/S by 0.6% during the fourth quarter. U.S. Capital Wealth Advisors LLC now owns 15,421 shares of the company’s stock valued at $1,595,000 after purchasing an additional 90 shares during the last quarter. Hancock Whitney Corp grew its stake in shares of Novo Nordisk A/S by 4.1% in the 1st quarter. Hancock Whitney Corp now owns 2,342 shares of the company’s stock valued at $373,000 after buying an additional 92 shares in the last quarter. Finally, Clarius Group LLC raised its holdings in shares of Novo Nordisk A/S by 0.5% during the 4th quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock valued at $1,914,000 after purchasing an additional 93 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.